He Weiling, Jiang Xuehua, Zhang Zhi-Rong
University of Wyoming School of Pharmacy, Laramie, Wyoming 82071, USA.
J Pharm Sci. 2008 Jun;97(6):2250-9. doi: 10.1002/jps.21148.
Thymopentin (Tp5) was loaded in poly-butylcyanoacrylate (PBCA) nanoparticles (NP) in order to enhance the oral bioavailability of Tp5. PBCA-Tp5-NP was prepared by nanoprecipitation methods. Dialyzing membrane method was employed to examine the in vitro release of PBCA-Tp5-NP in PBS, and Tp5 samples in the release medium were detected by HPLC. The cell proliferation test ((3)H-thymidine) was conducted to verify the PBCA-Tp5-NP bioactivity in vitro. The pharmacodynamical studies were performed on preimmunoinhibited rats and in flow cytometer. The size and the entrapment efficiency of PBCA-Tp5-NP were 178 +/- 39 nm and 92.21 +/- 1.08%, respectively. In vitro release data show that less than 60% Tp5 was released from lyophilized PBCA-Tp5-NP while 80% Tp5 was released from the colloidal PBCA-Tp5-NPs in 48 h. The proliferation test showed that PBCA-Tp5-NP had the similar effect as Tp5. The in vivo data showed that oral PBCA-Tp5-NPs had similar function as what intravenous Tp5 did. The oral bioavailability of Tp5 could be enhanced by PBCA nanoparticles. PBCA-Tp5-NP had the property of sustained-release and the efficacy of Tp5 was not changed after formulation.
为提高胸腺五肽(Tp5)的口服生物利用度,将其载入聚氰基丙烯酸丁酯(PBCA)纳米粒(NP)中。采用纳米沉淀法制备PBCA-Tp5-NP。用透析膜法考察PBCA-Tp5-NP在磷酸盐缓冲液(PBS)中的体外释放情况,并用高效液相色谱法(HPLC)检测释放介质中的Tp5样品。通过细胞增殖试验(³H-胸腺嘧啶核苷)验证PBCA-Tp5-NP的体外生物活性。在免疫抑制前的大鼠身上以及流式细胞仪上进行药效学研究。PBCA-Tp5-NP的粒径和包封率分别为178±39 nm和92.21±1.08%。体外释放数据表明,冻干的PBCA-Tp5-NP中Tp5的释放率在48小时内低于60%,而胶体状PBCA-Tp5-NP中Tp5的释放率为80%。增殖试验表明,PBCA-Tp5-NP与Tp5具有相似的作用。体内数据表明,口服PBCA-Tp5-NP与静脉注射Tp5具有相似的功能。PBCA纳米粒可提高Tp5的口服生物利用度。PBCA-Tp5-NP具有缓释特性,制剂后Tp5的药效不变。